FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069755814> ?p ?o ?g. }

• W2069755814 endingPage "1084" @default.
• W2069755814 startingPage "1079" @default.
• W2069755814 abstract "ObjectivesThis study evaluated the feasibility and outcomes of percutaneous transhepatic balloon angioplasty (PTBA) of the hepatic vein in the management of Budd-Chiari syndrome (BCS) secondary to hepatic venous outflow obstruction.MethodsFrom September 1996 to October 2008, 101 patients (52 males, 49 females) with BCS secondary to occlusion of the hepatic veins were prospectively treated using PTBA of the hepatic vein. Average age was 31.3 years (range, 15-57 years). Nineteen had concurrent inferior vena cava (IVC) obstruction. All the patients presented with symptomatic portal hypertension. PTBA, with or without stenting, was performed after hepatovenography.ResultsPTBA was successfully performed in 92 of the 101 patients. Sixty-eight patients underwent PTBA of right hepatic vein, followed by stent placement in two. PTBA was performed in 11 patients with left hepatic vein occlusion and in 13 patients with dominant accessory hepatic vein occlusion. The technical success rate was 92 of 101 (91%). Hepatic venous pressure was significantly decreased after balloon angioplasty/stenting (P < .01, paired t test). Symptoms were significantly improved in the 92 patients who had successful PTBA. Three patients had acute hepatic vein thrombosis during or after PTBA. Two patients sustained intraperitoneal bleeding from the transhepatic puncture track, and one had intrahepatic hematoma. Pulmonary embolism developed in one patient during the operation. All complications were managed nonoperatively. There were no perioperative deaths. Within 1 year, 74 of the 101 patients returned for follow-up, and 51 patients had follow-up at 2 years. The primary patency rates were 84% (62 of 74), 78% (58 of 74), and 76% (39 or 51) at 6, 12, and 24 months after PTBA, respectively. The secondary patency rates were 95% (70 of 74), 92% (68 of 74), and 84% (43 of 51) at 6, 12, and 24 months.ConclusionsPTBA of the hepatic vein is a safe and effective treatment of BCS. It is currently the most physiologic procedure, and the risk of postoperative encephalopathy is minimized because portal flow is not diverted. Midterm outcomes are satisfactory. Further investigation of the long-term outcomes is needed. This study evaluated the feasibility and outcomes of percutaneous transhepatic balloon angioplasty (PTBA) of the hepatic vein in the management of Budd-Chiari syndrome (BCS) secondary to hepatic venous outflow obstruction. From September 1996 to October 2008, 101 patients (52 males, 49 females) with BCS secondary to occlusion of the hepatic veins were prospectively treated using PTBA of the hepatic vein. Average age was 31.3 years (range, 15-57 years). Nineteen had concurrent inferior vena cava (IVC) obstruction. All the patients presented with symptomatic portal hypertension. PTBA, with or without stenting, was performed after hepatovenography. PTBA was successfully performed in 92 of the 101 patients. Sixty-eight patients underwent PTBA of right hepatic vein, followed by stent placement in two. PTBA was performed in 11 patients with left hepatic vein occlusion and in 13 patients with dominant accessory hepatic vein occlusion. The technical success rate was 92 of 101 (91%). Hepatic venous pressure was significantly decreased after balloon angioplasty/stenting (P < .01, paired t test). Symptoms were significantly improved in the 92 patients who had successful PTBA. Three patients had acute hepatic vein thrombosis during or after PTBA. Two patients sustained intraperitoneal bleeding from the transhepatic puncture track, and one had intrahepatic hematoma. Pulmonary embolism developed in one patient during the operation. All complications were managed nonoperatively. There were no perioperative deaths. Within 1 year, 74 of the 101 patients returned for follow-up, and 51 patients had follow-up at 2 years. The primary patency rates were 84% (62 of 74), 78% (58 of 74), and 76% (39 or 51) at 6, 12, and 24 months after PTBA, respectively. The secondary patency rates were 95% (70 of 74), 92% (68 of 74), and 84% (43 of 51) at 6, 12, and 24 months. PTBA of the hepatic vein is a safe and effective treatment of BCS. It is currently the most physiologic procedure, and the risk of postoperative encephalopathy is minimized because portal flow is not diverted. Midterm outcomes are satisfactory. Further investigation of the long-term outcomes is needed." @default.
• W2069755814 created "2016-06-24" @default.
• W2069755814 creator A5015877957 @default.
• W2069755814 creator A5019450834 @default.
• W2069755814 creator A5029514196 @default.
• W2069755814 creator A5037487659 @default.
• W2069755814 creator A5040984049 @default.
• W2069755814 creator A5043966917 @default.
• W2069755814 creator A5050238187 @default.
• W2069755814 creator A5055710091 @default.
• W2069755814 date "2009-11-01" @default.
• W2069755814 modified "2023-10-11" @default.
• W2069755814 title "Feasibility and midterm outcomes of percutaneous transhepatic balloon angioplasty for symptomatic Budd-Chiari syndrome secondary to hepatic venous obstruction" @default.
• W2069755814 cites W1584937528 @default.
• W2069755814 cites W1982116792 @default.
• W2069755814 cites W1982728410 @default.
• W2069755814 cites W1993679231 @default.
• W2069755814 cites W1996174720 @default.
• W2069755814 cites W2003895029 @default.
• W2069755814 cites W2029497230 @default.
• W2069755814 cites W2036421139 @default.
• W2069755814 cites W2049283453 @default.
• W2069755814 cites W2049371144 @default.
• W2069755814 cites W2059734662 @default.
• W2069755814 cites W2061982456 @default.
• W2069755814 cites W2098496422 @default.
• W2069755814 cites W2105700640 @default.
• W2069755814 cites W2112788045 @default.
• W2069755814 cites W2144990123 @default.
• W2069755814 cites W2149342199 @default.
• W2069755814 cites W4255132218 @default.
• W2069755814 doi "https://doi.org/10.1016/j.jvs.2009.06.049" @default.
• W2069755814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19703746" @default.
• W2069755814 hasPublicationYear "2009" @default.
• W2069755814 type Work @default.
• W2069755814 sameAs 2069755814 @default.
• W2069755814 citedByCount "42" @default.
• W2069755814 countsByYear W20697558142012 @default.
• W2069755814 countsByYear W20697558142013 @default.
• W2069755814 countsByYear W20697558142014 @default.
• W2069755814 countsByYear W20697558142015 @default.
• W2069755814 countsByYear W20697558142016 @default.
• W2069755814 countsByYear W20697558142017 @default.
• W2069755814 countsByYear W20697558142018 @default.
• W2069755814 countsByYear W20697558142019 @default.
• W2069755814 countsByYear W20697558142020 @default.
• W2069755814 countsByYear W20697558142021 @default.
• W2069755814 countsByYear W20697558142022 @default.
• W2069755814 countsByYear W20697558142023 @default.
• W2069755814 crossrefType "journal-article" @default.
• W2069755814 hasAuthorship W2069755814A5015877957 @default.
• W2069755814 hasAuthorship W2069755814A5019450834 @default.
• W2069755814 hasAuthorship W2069755814A5029514196 @default.
• W2069755814 hasAuthorship W2069755814A5037487659 @default.
• W2069755814 hasAuthorship W2069755814A5040984049 @default.
• W2069755814 hasAuthorship W2069755814A5043966917 @default.
• W2069755814 hasAuthorship W2069755814A5050238187 @default.
• W2069755814 hasAuthorship W2069755814A5055710091 @default.
• W2069755814 hasBestOaLocation W20697558141 @default.
• W2069755814 hasConcept C126322002 @default.
• W2069755814 hasConcept C126838900 @default.
• W2069755814 hasConcept C139059822 @default.
• W2069755814 hasConcept C141071460 @default.
• W2069755814 hasConcept C2776208725 @default.
• W2069755814 hasConcept C2776268601 @default.
• W2069755814 hasConcept C2777202286 @default.
• W2069755814 hasConcept C2777214474 @default.
• W2069755814 hasConcept C2778583881 @default.
• W2069755814 hasConcept C2778808290 @default.
• W2069755814 hasConcept C2780326628 @default.
• W2069755814 hasConcept C2780813298 @default.
• W2069755814 hasConcept C2781033279 @default.
• W2069755814 hasConcept C2910216633 @default.
• W2069755814 hasConcept C71924100 @default.
• W2069755814 hasConceptScore W2069755814C126322002 @default.
• W2069755814 hasConceptScore W2069755814C126838900 @default.
• W2069755814 hasConceptScore W2069755814C139059822 @default.
• W2069755814 hasConceptScore W2069755814C141071460 @default.
• W2069755814 hasConceptScore W2069755814C2776208725 @default.
• W2069755814 hasConceptScore W2069755814C2776268601 @default.
• W2069755814 hasConceptScore W2069755814C2777202286 @default.
• W2069755814 hasConceptScore W2069755814C2777214474 @default.
• W2069755814 hasConceptScore W2069755814C2778583881 @default.
• W2069755814 hasConceptScore W2069755814C2778808290 @default.
• W2069755814 hasConceptScore W2069755814C2780326628 @default.
• W2069755814 hasConceptScore W2069755814C2780813298 @default.
• W2069755814 hasConceptScore W2069755814C2781033279 @default.
• W2069755814 hasConceptScore W2069755814C2910216633 @default.
• W2069755814 hasConceptScore W2069755814C71924100 @default.
• W2069755814 hasIssue "5" @default.
• W2069755814 hasLocation W20697558141 @default.
• W2069755814 hasLocation W20697558142 @default.
• W2069755814 hasOpenAccess W2069755814 @default.
• W2069755814 hasPrimaryLocation W20697558141 @default.
• W2069755814 hasRelatedWork W2022082624 @default.
• W2069755814 hasRelatedWork W2024041283 @default.
• W2069755814 hasRelatedWork W2106777358 @default.
• W2069755814 hasRelatedWork W2160126565 @default.

• next